69843-13-6

Basic information

• Product Name: 1-METHYL-1H-PYRAZOL-4-YLAMINE
• Synonyms: ART-CHEM-BB B022860;ASINEX-REAG BAS 13529566;1-METHYL-1H-PYRAZOL-4-YLAMINE;AKOS PAO-0224;AKOS B022860;TIMTEC-BB SBB009607;1-methyl-1H-pyrazol-4-amine hydrochloride;4-Amino-1-methylpyrazole
• CAS NO: 69843-13-6
• Molecular Formula: C₄H₇N₃
• Molecular Weight: 97.12
• EINECS: 1592732-453-0
• Mol File: 69843-13-6.mol
• Article Data: 40

Chemical Properties

• Melting Point: 47-50℃
• Boiling Point: 231.4 °C at 760 mmHg
• Flash Point: >110 °C
• Appearance: /
• Density: 1.141 g/mL at 25 °C
• Vapor Pressure: 0.0624mmHg at 25°C
• Refractive Index: n20/D1.556
• Storage Temp.: ?20°C
• PKA: 3.70±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 1-METHYL-1H-PYRAZOL-4-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-1H-PYRAZOL-4-YLAMINE(69843-13-6)
• EPA Substance Registry System: 1-METHYL-1H-PYRAZOL-4-YLAMINE(69843-13-6)

Safety Data

• Hazard Codes: Xi
• Statements: 36/38
• Safety Statements: 26
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 69843-13-6(Hazardous Substances Data)

Usage

General Description

1-Methyl-1H-pyrazol-4-ylamine is a chemical entity primarily recognized in chemical and pharmaceutical research. 1-Methyl-1H-pyrazol-4-ylamine consists of a pyrazole core structure, which is a heterocyclic aromatic ring system composed of three carbon atoms and two nitrogen atoms, with an amine and a methyl group attached. Pyrazole derivatives, to which this compound belongs, are often studied for their diverse range of biological activities, giving 1-Methyl-1H-pyrazol-4-ylamine potential as a precursor for drug development. However, specific properties or uses for this compound may vary and should be determined by a qualified chemist.

InChI:InChI=1/C4H7N3/c1-7-3-4(5)2-6-7/h2-3H,5H2,1H3

Upstream product

• 54210-32-1 1-methyl-3-nitro-1H-pyrazole 
• 15803-02-8 4-bromo-1-methyl-1H-pyrazole 
• 3994-50-1 1-methyl-4-nitropyrazole 
• 2075-46-9 4-nitro-1H-pyrazole 
• 74-88-4 methyl iodide 

Downstream Products

• 1375455-13-2 5-methyl-N-(1-methyl-1H-pyrazol-4-yl)-4-(4-(methylsulfonyl)phenyl)pyrimidin-2-amine 
• 1428775-85-2 N-(1-methyl-1H-pyrazol-4-yl)-4-(3-nitrophenoxy)-5-(pyridin-3-yl)-7-{[2-(trimethylsilyl)ethoxy]methyl}-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1428776-29-7 5-chloro-N-(1-methyl-1H-pyrazol-4-yl)-4-(1-phenylethoxy)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 
• 1429297-40-4 C₁₉H₁₇Cl₂FN₄O₃ 
• 1428775-99-8 ((3,4-trans)-tert-butyl 3-((S)-1-((tert-butyldiphenylsilyl)oxy)ethyl)-4-(((5-chloro-2-((1-methyl-1H-pyrazol-4-yl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)methyl)pyrrolidine-1-carboxylate) 
• 1379176-31-4 phenyl (1-methyl-1H-pyrazol-4-yl)carbamate 

Relevant articles and documents

Design and synthesis of anti-tumor compounds containing ferulic acid-pyrazole skeleton

The invention discloses design and a preparation method of an anti-tumor compound containing a ferulic acid-pyrazole skeleton. The structure of the anti-tumor compound is shown as a formula in the specification.

Light-Triggered, Non-Centrosymmetric Self-Assembly of Aqueous Arylazopyrazoles at the Air–Water Interface and Switching of Second-Harmonic Generation

Trans-p-methoxy arylazopyrazole spontaneously forms non-centrosymmetric polar crystals, which reversibly undergo liquefaction upon photoisomerization to the cis-isomer. This liquid cis-isomer has a large electric dipole moment and is highly soluble in water (solubility up to ≈58 mM), which is remarkably higher than that of the trans-isomer (690 μM). Vis-light illumination of the aqueous cis-isomer generates macroscopically oriented, non-centrosymmetric crystals at the air–water interface. Polar crystals are also formed in sandwich glass cells (spacing, 20 μm) upon photo-induced crystallization of the liquid cis-isomer. The trans-crystals thus formed showed second harmonic generation (SHG) whose intensity is switched on/off in response to the photo-induced phase transition.

Novel 1H-pyrazolo[3,4-d]pyrimidin-6-amino derivatives as potent selective Janus kinase 3 (JAK3) inhibitors. Evaluation of their improved effect for the treatment of rheumatoid arthritis

Selective JAK3 inhibitors have been shown to have a potential benefit in the treatment of autoimmune disorders. Here we report the identification of a series of pyrazolopyrimidine derivatives as potent JAK3 inhibitors that exploit a unique cysteine (Cys909) residue in JAK3. Most of these compounds (13k, 13n and 13 t), displayed stronger anti-JAK3 kinase activity and selectivity than tofacitinib. Furthermore, the most active inhibitor 13t (IC50 = 0.1 nM), also exhibited favourable selectivity for JAK3 in a panel of 9 kinases which contain the same cysteine. In a series of cytokinestimulated cellular analysis, compound 13 t, could potently block the JAK3-STAT signaling pathway. Further biological studies, including cellular antiproliferative activity assays and a rat adjuvant-induced arthritis model for in vivo evaluation, also indicated its efficacy and low toxicity in the treatment of rheumatoid arthritis. The results of these experimental explorations suggested that 13t is a promising lead compound for the development of selective JAK3 inhibitor with therapeutic potential in rheumatoid arthritis.